Evidence map›Paper›PMID 38477020›Full record

ArticleThe Prostate2024

A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening.

Jian Gu, Lisly Chery, Graciela M Nogueras González, Chad Huff, Sara Strom, Jeffrey A Jones, Donald P Griffith, Steven E Canfield, Xuemei Wang, Xuelin Huang and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in The Prostate, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Towards equitable AI in oncology.Nature reviews. Clinical oncology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Jian GuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lisly CheryDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Graciela M Nogueras GonzálezDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Chad HuffDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sara StromDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeffrey A JonesDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-3059-6832
Donald P GriffithDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Steven E CanfieldDivision of Urology, UTHealth McGovern Medical School, Houston, Texas, USA.
Xuemei WangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xuelin HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pamela RobersonDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Qing H MengDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Patricia TroncosoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michael IttmannDepartment of Pathology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0003-4802-0978
Michael CovinskyDivision of Pathology, UTHealth McGovern Medical School, Houston, Texas, USA.
Michael ScheurerDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Margarita Irizarry RamirezDepartment of Graduate Studies, Clinical Laboratory Sciences, School of Health Professions, University of Puerto Rico, San Juan, Puerto Rico.ORCID 0000-0002-2177-5310
Curtis A PettawayDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-1697-1840
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USMichael E. DeBakey VA Medical Center · USThe University of Texas Health Science Center · USThe University of Texas Health Science Center at Houston · USUniversity of Puerto Rico System · PR

Funding

UPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI SHARON Hermes GIORDANO, REYNOLD Eugenio LOPEZ-ENRIQUEZ · 2002 to 2026
$36.9M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHARON Hermes GIORDANO · 2002 to 2026
$23.8M
TECHNOLOGIES AND RESOURCES FOR CORE LABORATORIESU54MD007587 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI LUCIANO, CARLOS A., WOJNA, VALERIE · 2012 to 2018
$23.2M
Tracking and Evaluation CoreU54GM133807 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI BONILLA-FELIX, MELVIN · 2020 to 2024
$17.7M
NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096300NIGMS NIH HHS U54 GM133807NIMHD NIH HHS 8U54MD 007587-03NIMHD NIH HHS U54 MD007587
6 · The paper itself

Abstract

backgroundAfrican American (AA) men have the highest incidence and mortality rates of prostate cancer (PCa) among all racial groups in the United States. While race is a social construct, for AA men, this overlaps with west African ancestry. Many of the PCa susceptibility variants exhibit distinct allele frequencies and risk estimates across different races and contribute substantially to the large disparities of PCa incidence among races. We previously reported that a single-nucleotide polymorphism (SNP) in 8q24, rs7824364, was strongly associated with west African ancestry and increased risks of PCa in both AA and Puerto Rican men. In this study, we determined whether this SNP can predict biopsy positivity and detection of clinically significant disease (Gleason score [GS] ≥ 7) in a cohort of AA men with suspected PCa.

methodsSNP rs7824364 was genotyped in 199 AA men with elevated total prostate-specific antigen (PSA) (>2.5 ng/mL) or abnormal digital rectal exam (DRE) and the associations of different genotypes with biopsy positivity and clinically significant disease were analyzed.

resultsThe variant allele carriers were significantly over-represented in the biopsy-positive group compared to the biopsy-negative group (44% vs. 25.7%, p = 0.011). In the multivariate logistic regression analyses, variant allele carriers were at a more than a twofold increased risk of a positive biopsy (odds ratio [OR] = 2.14, 95% confidence interval [CI] = 1.06-4.32). Moreover, the variant allele was a predictor (OR = 2.26, 95% CI = 1.06-4.84) of a positive biopsy in the subgroup of patients with PSA < 10 ng/mL and normal DRE. The variant allele carriers were also more prevalent in cases with GS ≥ 7 compared to cases with GS < 7 and benign biopsy.

conclusionsThis study demonstrated that the west African ancestry-specific SNP rs7824364 on 8q24 independently predicted a positive prostate biopsy in AA men who were candidates for prostate biopsy subsequent to PCa screening.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsBiopsyBlack or African AmericanEarly Detection of CancerHumansMalePolymorphism, Single NucleotideUnited StatesProstate-Specific AntigenAfrican Americanearly detectiongenetic polymorphismprosate cancer

Identifiers

PMID38477020
PMCPMC11240849
OpenAlexW4392752841

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.